WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
Apoptosis
Cell Cycle Proteins
/ metabolism
Cell Line, Tumor
Colorectal Neoplasms
/ drug therapy
Drug Resistance, Neoplasm
Humans
MAP Kinase Signaling System
/ drug effects
Mitogen-Activated Protein Kinases
/ metabolism
Nerve Tissue Proteins
/ metabolism
Oxaliplatin
/ pharmacology
Signal Transduction
WD40 Repeats
DNA damage repair
MAPK
WDR62
apoptosis
colorectal cancer
oxaliplatin resistance
proliferation
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
ppublish
Résumé
WD repeat domain 62 (WDR62) is involved in embryonic brain growth through regulation of glial and neural cell populations. WDR62 is also implicated in the carcinogenesis of various cancers. The role of WDR62 in progression and chemoresistance of colorectal cancer (CRC) was investigated. Firstly, oxaliplatin-resistant CRC cells (HCT116/R and HT29/R) were sequentially exposed to an increasing concentration of oxaliplatin. The results showed that WDR62 was elevated in CRC tissues, and oxaliplatin resistance conferred up-regulation of WDR62 in CRC cells. Knockdown of WDR62 reduced cell proliferation and promoted the apoptosis of oxaliplatin-resistant CRC cells. Moreover, silencing of WDR62 increased fluorescence intensity of γH2AX, and decreased protein expression of p-DNA-PK and Rad51 in the oxaliplatin-resistant CRC cells. The protein expression of p-ERK, p-JNK, and p-p38 in oxaliplatin-resistant CRC cells were down-regulated by knockdown of WDR62. In conclusion, silencing of WDR62 suppressed oxaliplatin resistance and DNA damage repair of CRC cells through inactivation of MAPK signaling.
Identifiants
pubmed: 35758246
doi: 10.1080/21655979.2022.2086381
pmc: PMC9342197
doi:
Substances chimiques
Cell Cycle Proteins
0
Nerve Tissue Proteins
0
WDR62 protein, human
0
Oxaliplatin
04ZR38536J
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14450-14459Références
Oncogene. 2019 Apr;38(15):2767-2777
pubmed: 30542121
JAMA. 2021 Feb 16;325(7):669-685
pubmed: 33591350
Biochim Biophys Acta Mol Cell Res. 2020 Jul;1867(7):118713
pubmed: 32246948
Oncotarget. 2017 Oct 10;8(61):103710-103730
pubmed: 29262595
Int J Biochem Cell Biol. 2022 Mar;144:106169
pubmed: 35093571
Int J Oncol. 2019 Jun;54(6):2222-2236
pubmed: 30942440
EBioMedicine. 2019 Oct;48:277-288
pubmed: 31631038
Chem Biol Interact. 2010 Dec 5;188(3):535-45
pubmed: 20708607
Mol Oncol. 2014 Feb;8(1):83-92
pubmed: 24145123
Front Oncol. 2021 Nov 23;11:764618
pubmed: 34888243
Ann Gastroenterol. 2014;27(1):9-14
pubmed: 24714764
Int J Mol Sci. 2020 Apr 16;21(8):
pubmed: 32316313
J Vis Exp. 2017 Nov 3;(129):
pubmed: 29155797
J Cell Physiol. 2018 Jul;233(7):5458-5467
pubmed: 29247488
Mol Biol Cell. 2010 Jan 1;21(1):117-30
pubmed: 19910486
World J Oncol. 2014 Jun;5(3):97-108
pubmed: 29147386
Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S42-6
pubmed: 19343149
Int J Mol Sci. 2020 Feb 07;21(3):
pubmed: 32046099
Oncol Rep. 2015 Sep;34(3):1087-96
pubmed: 26151224
Dis Markers. 2021 Jul 01;2021:9940274
pubmed: 34306258
J Ovarian Res. 2013 Jul 30;6(1):55
pubmed: 23898938
Mol Carcinog. 2017 Aug;56(8):1984-1991
pubmed: 28277612
Eur J Cancer. 2013 Nov;49(17):3752-62
pubmed: 23920402